Company intelligence / Profile preview

Advaite Inc.

Malvern, Pennsylvania, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Advaite has developed rapid point-of-care diagnostic kits for COVID‑19 using immunochromatography to detect IgM/IgG antibodies, aiming at mass screening. The company also holds an exclusive license option on a novel AMES Negative HDAC6 inhibitor from George Washington University targeting cancer. No published clinical results were found in the search results.

Therapeutic areas: Infectious DiseasesOncologyOther
Modalities: Small molecules (HDAC6 inhibitor)Point-of-care diagnostics (immunochromatography-based tests)
Industry: Biotech

Drug pipeline

3 assets

AdvaCoat

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Exclusive license option agreement with The George Washington University for novel HDAC6 inhibitor technology

Beyond the preview

Go deeper on Advaite Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advaite Inc..

Explore the full profile